News | July 27, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Revenue increased 11.4 per cent to Rs. 8,545 crore
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The new Zigly center features and offers comprehensive veterinary services
Subscribe To Our Newsletter & Stay Updated
